Publication: Risk and Management of Patients with Cancer and Heart Disease
dc.contributor.author | Hill, Loreena | |
dc.date.accessioned | 2023-08-17T05:42:49Z | |
dc.date.available | 2023-08-17T05:42:49Z | |
dc.date.issued | 2023 | |
dc.description.abstract | Abstract: Cancer and cardiovascular disease are two of the leading causes of global mortality and morbidity. Medical research has generated powerful lifesaving treatments for patients with cancer; however, such treatments may sometimes be at the expense of the patient’s myocardium, leading to heart failure. Anti-cancer drugs, including anthracyclines, can result in deleterious cardiac effects, significantly impacting patients’ functional capacity, mental well-being, and quality of life. Recognizing this, recent international guidelines and expert papers published recommendations on risk stratification and care delivery, including that of cardio-oncology services. This review will summarize key evidence with a focus on anthracycline therapy, providing clinical guidance for the non-oncology professional caring for a patient with cancer and heart failure. | en_US |
dc.identifier.other | 410-2023.02 | |
dc.identifier.uri | https://repository.mbru.ac.ae/handle/1/1331 | |
dc.language.iso | en | en_US |
dc.subject | Cardiotoxicity | en_US |
dc.subject | Anthracycline | en_US |
dc.subject | Risk Stratification | en_US |
dc.subject | Heart Failure | en_US |
dc.title | Risk and Management of Patients with Cancer and Heart Disease | en_US |
dc.type | Article | en_US |
dspace.entity.type | Publication | en_US |